A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- World Cancer Day 2020: Expert Speaks, Male Breast Cancer is a Growing Concernon February 3, 2020 at 3:45 am
... family history of breast cancer or presence in the family of genetic mutation associated with Breast cancer increases the risk of breast cancer. A history of exposure to radiation for treatment of ...
- Follicular Lymphoma Treatment Market Recent Industry Trends and Projected Industry Growth by 2026on February 3, 2020 at 2:38 am
Lymphoma is a type of cancer that begins in infection-fighting cells of the immune system, called lymphocytes. Follicular lymphoma particularly affects the white blood cells, called lymphocytes, and ...
- United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpointon February 3, 2020 at 2:00 am
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 3, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced topline results from the phase 2/3 DISTINCT clinical ...
- Medicare to Cover Breast Cancer Gene Sequencing: Coverage Updateson February 3, 2020 at 1:56 am
“We recognize that cancer patients shoulder a heavy burden, so we’re leaving no stone unturned in supporting women’s health and getting all patients the care they need.” In addition to helping ...
- Cervical Cancer Treatment Industry – Treatment, Outlook, Analysis, Research, Review To 2023on February 3, 2020 at 1:43 am
This report analyzes the cervical cancer treatment market by type (squamous cell carcinomas, adenocarcinomas, adenosquamous carcinomas), treatment (surgery, radiation therapy, chemotherapy, targeted ...
- Delegation from Ministry of State for FNC Affairs visits children receiving cancer treatment at Dubai Hospitalon February 3, 2020 at 1:37 am
A delegation from the Ministry of State for Federal National Council Affairs (MFNCA) marked World Cancer Day (February 4) with a visit to children receiving cancer treatment at Dubai Hospital, where ...
- Assessing 'stickiness' of tumor cells could improve cancer prognosison February 2, 2020 at 11:56 pm
follow-up treatments could be better tailored to the individual. The device that Engler's team built consists of a microfluidic chamber coated with an adhesive protein. Cancer cells are placed in ...
- Breast Cancer Survivor Provides Hair Treatments for Affected Womenon February 2, 2020 at 9:55 pm
A two-day “pity party" is all Tarsha Rodgers allowed herself after receiving her breast cancer diagnosis. After the self-pity came, she decided that she would help other women like her. In 2014, ...
- Prostate Cancer Diagnosis and Treatment Market Highlights Key Development Factors and Upcoming Trends During Forecast 2020 to 2027on February 2, 2020 at 5:43 pm
Ameco Research, Latest Research Report on titled "Global Prostate Cancer Diagnosis and Treatment Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2020 - 2027". In the coming ...
via Bing News